Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period. The primary end point is evaluation of progression free survival in HCC patients receiving immunotherapy. The secondary end point is to assess overall survival within the study period, duration of response and the response rate. The tertiary end point is to assess the toxicity profile.

NCT Number	NCT07088081
Lead Sponsor	Ain Shams University
Conditions	HCC - Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Therapy, Immune Checkpoint Inhibitor-Induced Dermatitis, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, Durvalumab
Enrollment	30 participants
Start Date	2025-06-01
Primary Completion	2026-06 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-28